253 related articles for article (PubMed ID: 30564416)
1. Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining.
Liu TP; Hsieh YY; Chou CJ; Yang PM
R Soc Open Sci; 2018 Nov; 5(11):181321. PubMed ID: 30564416
[TBL] [Abstract][Full Text] [Related]
2.
Liu TP; Hong YH; Yang PM
Oncotarget; 2017 Oct; 8(49):86168-86180. PubMed ID: 29156785
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive evaluation of connectivity methods for L1000 data.
Lin K; Li L; Dai Y; Wang H; Teng S; Bao X; Lu ZJ; Wang D
Brief Bioinform; 2020 Dec; 21(6):2194-2205. PubMed ID: 31774912
[TBL] [Abstract][Full Text] [Related]
4. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform.
Chopra G; Samudrala R
Curr Pharm Des; 2016; 22(21):3109-23. PubMed ID: 27013226
[TBL] [Abstract][Full Text] [Related]
5. Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database.
Barneh F; Jafari M; Mirzaie M
Brief Bioinform; 2016 Nov; 17(6):1070-1080. PubMed ID: 26490381
[TBL] [Abstract][Full Text] [Related]
6. Decoding Connectivity Map-based drug repurposing for oncotherapy.
Zhao Y; Chen X; Chen J; Qi X
Brief Bioinform; 2023 May; 24(3):. PubMed ID: 37068308
[TBL] [Abstract][Full Text] [Related]
7. Updates to Binding MOAD (Mother of All Databases): Polypharmacology Tools and Their Utility in Drug Repurposing.
Smith RD; Clark JJ; Ahmed A; Orban ZJ; Dunbar JB; Carlson HA
J Mol Biol; 2019 Jun; 431(13):2423-2433. PubMed ID: 31125569
[TBL] [Abstract][Full Text] [Related]
8. L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies.
Sendama W
Comput Struct Biotechnol J; 2020; 18():3947-3949. PubMed ID: 33312454
[TBL] [Abstract][Full Text] [Related]
9. Repurposing natural products as novel HDAC inhibitors by comparative analysis of gene expression profiles.
Byun MR; Lee DH; Jang YP; Lee HS; Choi JW; Lee SK
Phytomedicine; 2019 Jun; 59():152900. PubMed ID: 30974310
[TBL] [Abstract][Full Text] [Related]
10.
Asano T; Chelvanambi S; Decano JL; Whelan MC; Aikawa E; Aikawa M
Front Cardiovasc Med; 2022; 9():842641. PubMed ID: 35402570
[TBL] [Abstract][Full Text] [Related]
11. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective.
Zhang W; Bai Y; Wang Y; Xiao W
Curr Pharm Des; 2016; 22(21):3171-81. PubMed ID: 26907941
[TBL] [Abstract][Full Text] [Related]
12. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.
Sumi NJ; Ctortecka C; Hu Q; Bryant AT; Fang B; Remsing Rix LL; Ayaz M; Kinose F; Welsh EA; Eschrich SA; Lawrence HR; Koomen JM; Haura EB; Rix U
Cell Chem Biol; 2019 Sep; 26(9):1240-1252.e11. PubMed ID: 31257184
[TBL] [Abstract][Full Text] [Related]
13. Polypharmacology - foe or friend?
Peters JU
J Med Chem; 2013 Nov; 56(22):8955-71. PubMed ID: 23919353
[TBL] [Abstract][Full Text] [Related]
14. Reconciling multiple connectivity scores for drug repurposing.
Samart K; Tuyishime P; Krishnan A; Ravi J
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013329
[TBL] [Abstract][Full Text] [Related]
15. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.
Ravikumar B; Aittokallio T
Expert Opin Drug Discov; 2018 Feb; 13(2):179-192. PubMed ID: 29233023
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacology of Approved Anticancer Drugs.
Amelio I; Lisitsa A; Knight RA; Melino G; Antonov AV
Curr Drug Targets; 2017; 18(5):534-543. PubMed ID: 26926468
[TBL] [Abstract][Full Text] [Related]
17. Medicinal Polypharmacology in the Clinic - Translating the Polypharmacolome into Therapeutic Benefit.
Rafehi M; Möller M; Ismail Al-Khalil W; Stefan SM
Pharm Res; 2024 Mar; 41(3):411-417. PubMed ID: 38366233
[TBL] [Abstract][Full Text] [Related]
18. Polypharmacology: The science of multi-targeting molecules.
Kabir A; Muth A
Pharmacol Res; 2022 Feb; 176():106055. PubMed ID: 34990865
[TBL] [Abstract][Full Text] [Related]
19. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Subramanian A; Narayan R; Corsello SM; Peck DD; Natoli TE; Lu X; Gould J; Davis JF; Tubelli AA; Asiedu JK; Lahr DL; Hirschman JE; Liu Z; Donahue M; Julian B; Khan M; Wadden D; Smith IC; Lam D; Liberzon A; Toder C; Bagul M; Orzechowski M; Enache OM; Piccioni F; Johnson SA; Lyons NJ; Berger AH; Shamji AF; Brooks AN; Vrcic A; Flynn C; Rosains J; Takeda DY; Hu R; Davison D; Lamb J; Ardlie K; Hogstrom L; Greenside P; Gray NS; Clemons PA; Silver S; Wu X; Zhao WN; Read-Button W; Wu X; Haggarty SJ; Ronco LV; Boehm JS; Schreiber SL; Doench JG; Bittker JA; Root DE; Wong B; Golub TR
Cell; 2017 Nov; 171(6):1437-1452.e17. PubMed ID: 29195078
[TBL] [Abstract][Full Text] [Related]
20. MTLD, a Database of Multiple Target Ligands, the Updated Version.
Chen C; Wu M; Cen S; Wu J; Zhou J
Molecules; 2017 Sep; 22(9):. PubMed ID: 28878188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
